Navigation Links
ResMed Wins Initial Decision in ITC Patent Infringement Action
Date:8/24/2014

SYDNEY and SAN DIEGO, Aug. 24, 2014 /PRNewswire/ -- An administrative law judge at the International Trade Commission (ITC) ruled Friday August 22 in a patent infringement case brought by ResMed (NYSE: RMD) against Chinese medical device manufacturer BMC Medical Co., Ltd., that each of nine BMC products named in the action infringes one or more ResMed patents.  As a result, ITC Judge Thomas Pender recommended that the ITC ban BMC and its U.S. distributor, 3B Medical, from importing or selling any of the infringing BMC products in the United States.  Judge Pender also recommended a cease and desist order that would enjoin BMC and 3B from selling, advertising, marketing, storing or testing the infringing products in the United States.  ResMed is the innovation leader and pioneer in designing and manufacturing devices for the treatment of sleep-disordered breathing.

Judge Pender found that BMC's InH2 humidifier, as well as original and redesigned versions of the following BMC masks infringe ResMed's patents:

  • iVolve nasal mask
  • iVolve N2 nasal mask
  • Willow nasal pillows mask
  • iVolve full face mask
  • "The Judge's decision is not just a victory for ResMed and the product innovation that is core to our brand, but it's also a win for patients who deserve high quality, comfortable care," said David Pendarvis, ResMed chief administrative officer and global general counsel. "We will continue innovating and continue protecting our intellectual property anywhere we identify infringement."

    About ResMed:
    ResMed changes lives by developing, manufacturing and distributing medical equipment for treating, diagnosing, and managing sleep-disordered breathing, COPD, and other chronic diseases. We develop innovative products and solutions to improve the health and quality of life of those who suffer from these conditions, and we work to raise awareness of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.Contacts: For News Media For InvestorsGretchen Griswold

    Agnes LeeDirector, Global Corporate Communications

    Senior Director, Investor RelationsO: 858-836-6789

    O: 858-836-5971news@resmed.com 

    investorrelations@resmed.comLogo - http://photos.prnewswire.com/prnh/20140310/LA79234LOGO-a


    '/>"/>
    SOURCE ResMed
    Copyright©2014 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ResMed Inc. Announces Plan To Initiate Dividend And Update On Chief Executive Officer Succession
    2. ResMed Launches Narval™ CC Mandibular Repositioning Device in the US
    3. ResMed Announces Conference Call And Webcast To Discuss Fourth Quarter And Fiscal Year-End 2012 Results
    4. ResMed Inc. Announces Record Financial Results For The Quarter And Twelve Months Ended June 30, 2012
    5. ResMed Inc. Announces Record Financial Results for the Quarter Ended September 30, 2012
    6. ResMed Inc. Announces Exchange Rate For Upcoming Dividend Payment
    7. ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended December 31, 2012
    8. Buoyed by Forecasts, Where 2013 Leads - Research Report on ResMed Inc., Zimmer Holdings, Inc., Waters Corporation, Covidien PLC, and Medtronic, Inc.
    9. ResMed Takes Action to Enforce Patents
    10. ResMed Announces Conference Call And Webcast To Discuss Third Quarter 2013 Results
    11. ResMed Noninvasive Ventilation Device Cleared by FDA for COPD Treatment
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2016)... , May 24, 2016   ... demonstrating non-inferiority in overall bowel cleansing and superiority in ... c leansing of the ... ) , Norgine B.V. today announced new positive ... PEG and ascorbate bowel preparation) versus standard 2 litre PEG with ...
    (Date:5/24/2016)... 2016 Celsion Corporation (NASDAQ: ... provided an update on its ongoing OVATION study, ... GEN-1, the Company,s DNA-based immunotherapy, with the standard ... with advanced ovarian cancer who will undergo neoadjuvant ... an IL-12 DNA plasmid vector formulated as a ...
    (Date:5/24/2016)... , May 24, 2016 ... ™ , la première endoprothèse ... cathéters destinés à l,intervention portant sur les ...   OrbusNeich, entreprise mondiale spécialisée ... de changer la vie, a élargi son ...
    Breaking Medicine Technology:
    (Date:5/27/2016)... ... May 27, 2016 , ... W.S. Badger Co. Inc ... that it has been recognized as one of the best small businesses for new ... as one of nine small businesses providing progressive benefits to new parents on the ...
    (Date:5/27/2016)... ... May 27, 2016 , ... With over 60 percent of acute stroke ... a sustainable product to aid in the rehabilitation process has steadily increased. Ekso Bionics ... individuals with hemiplegia due to stroke. , Ekso Bionics has now received clearance from ...
    (Date:5/27/2016)... ... May 27, 2016 , ... An ... bolstered by inspiring human-interest stories, courtesy of awareness-driven celebrities and thought leaders. It ... leading advocates, associations and industry leaders such as Bioness. , As patients ...
    (Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
    (Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... Aimed at ... human interest stories, which come courtesy of leaders in the nursing and health care ... from leading advocates and associations—namely Abilene Christian University. , As the nursing industry ...
    Breaking Medicine News(10 mins):